U.K. Vaccine Plan On Track After EU Export Spat, Truss Says
(Bloomberg) --
The U.K.'s supply of vaccines is secure and the country will stick to its rollout timetable, International Trade Secretary Liz Truss said.
Her comments came after the European Union's executive arm announced it would require vaccine makers to obtain authorization before sending shots manufactured in the bloc to some other countries. The spat raised concerns over the provision of supplies of the Pfizer Inc. and BioNTech SE shot, manufactured in Belgium, to the U.K.
“We are absolutely confident we can continue to deliver our program,” Truss said in a Sky News interview. “We have received assurances from the EU that those contracts won't be disrupted. And now I think we need to move forward, working together.”
A record number of almost 600,000 people in the U.K. received their first dose of the vaccine on Saturday, taking the total figure to 8,977,329, government data show.
The origin of the dispute over vaccine exports is AstraZeneca Plc's decision to prioritize Britain over the EU following a Belgian production glitch, in what Brussels claims was a breach of contract. After a flurry of activity, AstraZeneca agreed to deliver 9 million additional vaccine doses to the European Union in the first quarter of this year, bringing the total to 40 million for the quarter, European Commission President Ursula von der Leyen said Sunday on Twitter.
‘Lessons to Be Learned'
A threat by the EU to unilaterally trigger emergency clauses in its post-Brexit accord with the U.K. as part of the dispute was “unacceptable” and “very foolish,” former Prime Minister Tony Blair told Sky's Sophy Ridge earlier on Sunday. He said the move, which officials have since backtracked on, risked endangering Ireland's 1998 Good Friday Agreement peace deal.
Irish Taoiseach Micheal Martin told the BBC that people had been “blindsided” by the threat and that there were “a lot of lessons to be learned.” Even so, he condemned how AstraZeneca had handled its EU vaccine contract so far.
“The point was transparency in terms of the relationship between AstraZeneca and the EU Commission,” he said. “There's a very fair point there which cannot be brushed aside either. The problem is the commission took the wrong mechanism in revoking Article 16 of the protocol to deal with it.”
President von der Leyen on Sunday held a video call with chief executives of pharmaceutical companies to discuss how vaccines could be more rapidly deployed, manufactured and approved in the future.
“The pandemic highlighted that manufacturing capacities are a limiting factor. It is essential to address these challenges,” the commission said in a statement after the call. It added that “the emergence of variants of concern raises the imminent threat of reduced efficacy of recently approved vaccines.”
Despite the U.K.'s progress with the vaccine roll out, British authorities are so far struggling to contain the virus. A further 587 deaths were reported Sunday and it was announced that Captain Sir Tom Moore, the 100-year-old veteran who has raised almost 40 million pounds ($55 million) for the nation's health service, was admitted to hospital after testing positive for Covid-19.
Read more: Faced With a Vaccine Emergency, the EU Made an Enemy of Everyone
©2021 Bloomberg L.P.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.